Les parts du chiffre d'affaires sont des estimations pour quarter ended 2026-03-31, pas des chiffres tirés d'un document officiel.
Established Pharmaceutical Products
Branded generic medicines sold outside the United States, including treatments for digestive conditions, women's health, heart and metabolic conditions, pain, and respiratory infections.
Diagnostic systems and tests
Laboratory instruments, test kits, and rapid tests used to help detect or monitor conditions such as infections, cancer, heart problems, and thyroid disorders.
Nutrition products
Infant formula, adult nutrition drinks and powders, and products used for feeding patients in healthcare institutions, including Similac, Ensure, and PediaSure.
Heart and other medical devices
Products include pacemakers, heart valves, devices used to treat narrowed blood vessels, and implanted devices for chronic pain or movement disorders.
FreeStyle Libre
A continuous glucose monitoring system with a sensor worn on the body to measure glucose levels for people with diabetes.
Cologuard
A stool-based test used to screen for colorectal cancer; Abbott discussed it on its earnings call as part of its cancer diagnostics business.
Abbott develops, makes, and sells healthcare products around the world. Its businesses include branded generic medicines sold outside the United States, diagnostic tests and equipment, nutrition products, and devices for heart conditions, diabetes, and other needs. Its buyers include healthcare providers, distributors, retailers, government agencies, and consumers.
Construit à partir des documents déposés par Abbott Laboratories auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
The themes Abbott Laboratories is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
108,53 $US+1,2 %clôture 13 nov.
Chiffres jusqu’au 30 septembre 2026, issus du 10-Q déposé le 4 novembre 2026
Abbott makes and sells medicines, diagnostic tests, nutrition products, and medical devices.
Grade B
La bande sous le cours montre la note à chaque date, établie uniquement à partir des documents publics à ce moment-là.
Affichage de 2 trimestres sur 40 de l’historique des notes de Abbott Laboratories. Les 38 autres remontent jusqu’à novembre 2016.
